[
  {
    "ts": null,
    "headline": "Abbott Laboratories: A Key Reduction in Robert Bruce's Portfolio",
    "summary": "Exploring the Strategic Moves of a Seasoned Value Investor",
    "url": "https://finnhub.io/api/news?id=f5173688bc4535e5e1164096c0300f085d6a92a8cbd4345c63ef120b70a1cf69",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771023688,
      "headline": "Abbott Laboratories: A Key Reduction in Robert Bruce's Portfolio",
      "id": 139091179,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Exploring the Strategic Moves of a Seasoned Value Investor",
      "url": "https://finnhub.io/api/news?id=f5173688bc4535e5e1164096c0300f085d6a92a8cbd4345c63ef120b70a1cf69"
    }
  },
  {
    "ts": null,
    "headline": "Where is AbbVie Inc. (ABBV) Headed According to the Street?",
    "summary": "AbbVie Inc. (NYSE:ABBV) is one of the best medical research stocks to buy according to hedge funds. AbbVie Inc. (NYSE:ABBV) received rating updates from Guggenheim and UBS on February 5, with Guggenheim reaffirming a Buy rating on the stock with a $242 price target and UBS revising the price target to $230 from $240 while […]",
    "url": "https://finnhub.io/api/news?id=03d47221693bd2bab65096005af00dc1603436d8c6628e490eecbbcb3f49f4cf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770994652,
      "headline": "Where is AbbVie Inc. (ABBV) Headed According to the Street?",
      "id": 139085006,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie Inc. (NYSE:ABBV) is one of the best medical research stocks to buy according to hedge funds. AbbVie Inc. (NYSE:ABBV) received rating updates from Guggenheim and UBS on February 5, with Guggenheim reaffirming a Buy rating on the stock with a $242 price target and UBS revising the price target to $230 from $240 while […]",
      "url": "https://finnhub.io/api/news?id=03d47221693bd2bab65096005af00dc1603436d8c6628e490eecbbcb3f49f4cf"
    }
  },
  {
    "ts": null,
    "headline": "Merck stock upside: Why Deutsche Bank sees 26% growth despite Keytruda patent",
    "summary": "Investing.com -- Merck (NYSE: MRK) stock rose 2% Friday morning after Deutsche Bank analyst James Shin upgraded the pharmaceutical giant from Hold to Buy, setting a price target of $150.00, up from $115.00.",
    "url": "https://finnhub.io/api/news?id=b10722ec632a4ca5c9281c2f36b849957bc9cec7f6d6344db2e46cf5b0070504",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770987636,
      "headline": "Merck stock upside: Why Deutsche Bank sees 26% growth despite Keytruda patent",
      "id": 139081170,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Investing.com -- Merck (NYSE: MRK) stock rose 2% Friday morning after Deutsche Bank analyst James Shin upgraded the pharmaceutical giant from Hold to Buy, setting a price target of $150.00, up from $115.00.",
      "url": "https://finnhub.io/api/news?id=b10722ec632a4ca5c9281c2f36b849957bc9cec7f6d6344db2e46cf5b0070504"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. (ABBV) Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium Transcript",
    "summary": "AbbVie Inc. (ABBV) Piper Sandler Virtual Novel Targets in Immunology Symposium February 13, 2026 10:00 AM ESTCompany ParticipantsRoopal Thakkar - Executive...",
    "url": "https://finnhub.io/api/news?id=995b1e5f1cdf20ab3f5b872a64ccbd9b14b38a336e04d6e8ef95d81c7dfd03b7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770987465,
      "headline": "AbbVie Inc. (ABBV) Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium Transcript",
      "id": 139086868,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "AbbVie Inc. (ABBV) Piper Sandler Virtual Novel Targets in Immunology Symposium February 13, 2026 10:00 AM ESTCompany ParticipantsRoopal Thakkar - Executive...",
      "url": "https://finnhub.io/api/news?id=995b1e5f1cdf20ab3f5b872a64ccbd9b14b38a336e04d6e8ef95d81c7dfd03b7"
    }
  },
  {
    "ts": null,
    "headline": "CNBC Daily Open: The AI fear spreads — real estate, trucking and logistics are its latest victims",
    "summary": "The latest victims of artificial intelligence are real estate, trucking and logistics stocks, joining financial and software stocks in plunging on AI fears.",
    "url": "https://finnhub.io/api/news?id=a2694af90e7a15905bafe12b659cea38ec8146928874791210bb1c210052979c",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770951317,
      "headline": "CNBC Daily Open: The AI fear spreads — real estate, trucking and logistics are its latest victims",
      "id": 139085877,
      "image": "https://image.cnbcfm.com/api/v1/image/108264520-17708280672026-02-11t163050z_1656599808_rc2qjjatwxq2_rtrmadp_0_usa-stocks.jpeg?v=1770828653&w=1920&h=1080",
      "related": "ABBV",
      "source": "CNBC",
      "summary": "The latest victims of artificial intelligence are real estate, trucking and logistics stocks, joining financial and software stocks in plunging on AI fears.",
      "url": "https://finnhub.io/api/news?id=a2694af90e7a15905bafe12b659cea38ec8146928874791210bb1c210052979c"
    }
  },
  {
    "ts": null,
    "headline": "West Pharmaceutical Services (WST) Is Up 5.2% After Strong 2025 Results And 2026 Organic Growth Outlook",
    "summary": "In the past week, West Pharmaceutical Services reported its 2025 results, with full-year sales rising to US$3.07 billion and net income edging up to US$493.7 million, while also issuing 2026 guidance that calls for first-quarter net sales of US$770 million to US$790 million and full-year net sales of US$3.22 billion to US$3.28 billion, including a foreign-exchange benefit. An important detail in that outlook is that organic net sales growth is expected to outpace reported growth,...",
    "url": "https://finnhub.io/api/news?id=be6c484e53a70478fd31bcab3aa3d4c620728c6e01e0d194e4d05b2f1ef68068",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770942175,
      "headline": "West Pharmaceutical Services (WST) Is Up 5.2% After Strong 2025 Results And 2026 Organic Growth Outlook",
      "id": 139077104,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "In the past week, West Pharmaceutical Services reported its 2025 results, with full-year sales rising to US$3.07 billion and net income edging up to US$493.7 million, while also issuing 2026 guidance that calls for first-quarter net sales of US$770 million to US$790 million and full-year net sales of US$3.22 billion to US$3.28 billion, including a foreign-exchange benefit. An important detail in that outlook is that organic net sales growth is expected to outpace reported growth,...",
      "url": "https://finnhub.io/api/news?id=be6c484e53a70478fd31bcab3aa3d4c620728c6e01e0d194e4d05b2f1ef68068"
    }
  }
]